Gender
Conditions
Keywords
P-glycoprotein, MC225, [18F]MC225, PET
Brief summary
P-gp is one of the main efflux transporters at the blood-brain barrier and is responsible for the transport of a variety of neurotoxic substances, including pharmaceuticals. Multiple studies report gender differences in therapeutic outcomes, toxicity and side effects for many drug agents. P-gp plays an important role in the bio-availability, drug distribution, metabolism and elimination of pharmaceuticals labelled as P-gp substrates (e.g. the majority of antidepressants and antipsychotics). A difference in P-gp function was already reported in hepatic P-gp expression. The aim of the current study is to evaluate the influence of gender on cerebral P-gp function. Outcomes of this study can be of great importance in gender-based prescription of P-gp substrate pharmaceuticals.
Interventions
DRUG[18F]MC225
\[18F\]MC225 PET scan
Sponsors
University Medical Center Groningen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Two groups of healthy volunteers (5 male, 5 female)
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers
Exclusion criteria
* Use of medication with a known effect on the BBB P-glycoprotein transporter * Any history of neurological or psychiatric conditions affecting the BBB P-glycoprotein function
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PET kinetic modeling outcome parameters [18F]MC225 | 60 minutes after administration [18F]MC225 | volume of distribution, K1, k2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PET kinetic modeling outcome parameters [15O]H2O | 10 minutes after administration of [15O]H2O | K1 to evaluate Cerebral Blood Flow (CBF) |
Contacts
Primary ContactPascalle Mossel, Msc
Outcome results
None listed